INTRODUCTION
It has been well known that drug-proteins interactions greatly influence the absorption, distribution, metabolism, and excretion properties of drugs. Serum albumins are the most abundant protein in the circulatory system of a wide variety of organisms and play an important role in the transport and deposition of a wide variety of drugs [1] . Thus, an understanding of the features of a variety of pharmaceutical interactions with albumin may provide new insights to drug therapy and design. Consequently, much attention has been focused on the binding between drugs and albumin. Bovine serum albumin (BSA) was usually chosen as model protein because BSA is low cost and ready availability, while has a structural homology with human serum albumin [2] .
Efonidipine hydrochloride (efonidipine, NZ-105, shown in Fig.1 ) is a newly synthesized 1,4-dihydropyridine derivative that is used as an antihypertensive and antianginal agent. It has a potent vasodilating effect on vascular smooth muscle and a long-lasting hypotensive effect with a very slow onset. NZ-105 has also been found to have a chronotropic effect, which may suppress tachycardia [3] . NZ-105 has less side effects and is better tolerated in the treatment of hypertension with renal [4] . NZ-105, thus, became a new generation of agent in the treatment of hypertension with chronic renal disease. However, detailed information on the binding between BSA and NZ-105, which is apparently useful in understanding the pharmacokinetic and pharmacodynamic mechanisms of the drug, has not yet to be conducted. Therefore, such study should be valuable from the perspective of medical importance.
Application of the spectral methods can reveal the binding of drug and albumin in low concentration under physiological conditions. The fluorescence quenching technique is often used to monitor the molecular interactions because of its high sensitivity, reproducibility and relatively easy to use. In this paper, we investigated the interactions of NZ-105 with BSA as well as the impacts of common metal ions on the interaction by fluorescence spectroscopy. Additionally, binding of NZ-105 with BSA in the presence of fluorescence probe 8-anilino-1-naphthalein-sulphonic acid (ANS) was conducted. Effects of NZ-105 on conformational changes of BSA were investigated by synchronous fluorescence spectroscopy and circular dichroism (CD).
II. MATERIALS AND METHODS

A. Chemicals and Apparatus
Bovine serum albumin (BSA, >96%, essentially fatty acid free, lyophilized power) and 8-anilino-1-naphthalein-sulphonic acid sodium salt (ANS) were purchased from Sigma (USA). Efonidipine was obtained from Garlin Pharmaceutical Co. (Beijing, China). Fluorescence and synchronous measurements were performed using a 1 cm quartz cell on a RF-5301PC spectrofluorophotometer (Shimadzu, Japan) equipped with a SB-11 water bath (Eyela). The absorption spectrum was collected on a UV-2250 UV-Vis spectrophotometer (Shimadzu, Japan). The CD measurements were recorded on a JASCO-J-810 spectropolarimeter (JASCO, Japan) using a 0.1 cm quartz cell.
B. Procedures
2.5 mL 10 µM BSA was added to the quartz cell, NZ-105 was then gradually added to the cell and the concentrations of NZ-105 ranged from 5 to 50 µM with or without metal ions. Fluorescence emission spectra were recorded at three temperatures upon excitation at 295 nm. Synchronous fluorescence spectra of BSA with various concentrations of
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NZ-105 were obtained from 300 to 400nm when ǻȜ=60nm and from 280 to 350nm when ǻȜ=15nm. CD spectra of BSA in the absence and presence of NZ-105 were recorded from 200 to 280nm at 0.2 nm intervals with five scans averaged for each spectrum.Next, BSA concentration was kept fixed at 10 µM and the concentration of NZ-105 or ANS was varied from 2.5 to 25 µM, respectively. Fluorescence spectra of BSA were recorded from 300-500 nm as excitation at 295 nm. Then, BSA and ANS concentrations were fixed at 10 and 20 µM, respectively. NZ-105 was then gradually added to above BSA-ANS mixture. Fluorescence spectra of ANS were recorded from 390 to 550 nm after excitation at 370 nm.
III. RESULTS AND DISCUSSION
A. Fluorescence studies
The intrinsic fluorescence of BSA when excited at 295 nm is mainly due to the presence of the two trytophan residues: Trp-134 and Trp-212. Trp-212 is located within a hydrophobic binding pocket in sub-domain IIA of the protein, whereas Trp-134 is located on the surface of the albumin molecule and more exposed to the environment [5] . Though tyrosine residue can also contribute to fluorescence, it presents very weak emission when excited at 295 nm.
The fluorescence spectra of BSA were recorded in the presence of increasing amount of NZ-105 (Fig.2 ). As shown in Fig. 2 , the fluorescence intensity of BSA decreased regularly with the increasing concentration of NZ-105, while the emission maximum and shape of the peaks kept almost unchanged. This indicated that NZ-105 could bind to the BSA without altering the environment in the vicinity of the chromophore residues.
The binding parameters were then obtained according to the following equation:
where n is the number of binding sites, K A is the binding constant or the apparent association constant for drug-protein interaction. Values of n and K A can thereby be determined from the intercept and slope by plotting log(
. Values of n and K A are illustrated in Table 1 . The value of n is approximately equal to 1, indicating that there is one 
B. Stern-Volmer analysis
Fluorescence quenching is usually classified as dynamic quenching and static quenching. Dynamic quenching, or collisional quenching, results from collision between fluorophore and quencher. Static quenching is due to groundstate complex formation between fluorophore and quencher. To figure out the mechanism of binding between BSA and NZ-105, fluorescence intensity data was analyzed by SternVolmer equation:
where F and F 0 are the fluorescence intensity with and without the quencher (drug), K SV the Stern-Volmer quenching constant, and [Q] is the concentration of drug. If the resulted plots exhibited a good linear relationship, it is generally indicative of the purely collisional quenching process or static quenching process.
However, the Stern-Volmer plot shows minor positive deviation (Fig.3) indicating the presence of both static and dynamic quenching. Therefore, the data was then processed based on modified Stern-Volmer equation:
where V is the static quenching constant and the value of V can be obtained from Eq.3 by plotting
for varying V until a linear plot is acquired (Fig.3) . The K sv can be then obtained from slope. Values of V and K sv at different temperatures (298, 304 and 310 K) are presented in Table 2 .
As can be seen from Table 2 , the values of K sv is much larger than that of V, suggesting that the overall quenching is dominated by dynamic quenching, though a small static quenching component contributing to the positive deviation of Stern-Volmer plot [6] . This small part of static quenching can be explained as a minor fraction of the quencher molecule is very near to, or in contact with the fluorescent molecule at the exact moment it happens to be excited.
C. Type of interaction force between efonidipine and BSA
The interaction forces between drugs and biomolecules include hydrophobic force, electrostatic interactions, van der Waals interactions, hydrogen bonds, etc. In order to illuminate the interaction force of NZ-105 with BSA, the thermodynamic parameters, that is, free energy changes (ǻG 0 ), enthalpy changes (ǻH 0 ), and entropy changes (ǻS 0 ) of interactions were calculated from the following equations:
where, K corresponds to the binding constant K A and R is the gas constant. The data of thermodynamic parameters were summarized in Table 3 . The negative value of ǻG 0 means that NZ-105 binding to BSA is a spontaneous process. The positive ǻH 0 and ǻS 0 values indicate that the acting force between NZ-105 and BSA was mainly hydrophobic interaction force. Thus, the non-polarity hydrophobic group of serum albumins may have main effect on the binding of NZ-105 and serum albumins. This along with the number of binding site may infer that the binding site for NZ-105 on BSA is mainly on the Trp-212 residue which located within a hydrophobic binding pocket of the protein.
D. Conformational investigations
Synchronous fluorescence spectra (Fig. 4) of BSA with various amounts of NZ-105 were measured to explore the conformational change of BSA upon addition of NZ-105. When the ǻȜ between excitation wavelength and emission wavelength were fixed at 15 and 60 nm, the synchronous fluorescence spectra give the characteristic information of tyrosine and tryptophan residues, respectively. It can be seen from Fig. 4 that the quenching of the fluorescence intensity of tryptophan residues is stronger than that of tyrosine residues, indicating that tryptophan residues contribute greatly to the intrinsic fluorescence of BSA. It is also noted that there is a red shift of tryptophan residues fluorescence emission maximum upon addition of NZ-105, whereas the emission maximum of tyrosine kept unchanged. The red shift indicates that the conformation of BSA was changed and the hydrophobicity was decreased. The decreased hydrophobicity may attribute to the binding of NZ-105 to BSA molecules, which caused the extension of peptide strand.
To further confirm the conformational change of BSA upon addition of NZ-105, CD spectra of BSA with and without NZ-105 were measured. As shown in Fig. 5 , the CD spectra of BSA exhibited two negative bands in the UV region at 209 and 222 nm, characteristic of Į-helix structure of protein. The binding of NZ-105 to BSA decreases the intensity of both bands, indicating the decrease of the α-helical content in protein. That is, NZ-105 bound with the amino acid residue of the main polypeptide chain of BSA and destroyed their hydrogen bonding networks [9] . Nevertheless, the CD spectra of BSA in presence and absence of NZ-105 are similar in shape, implying that the structure of BSA after binding of BSA with NZ-105 is also predominantly α-helical.
E. Energy transfer from BSA to efonidipine
According to Föster's theory, the energy transfer effect is related not only to the distance between the acceptor and donor (r 0 ), but also to the critical energy transfer distance (R 0 ), that is:
where E is the energy transfer efficiency, R 0 is the critical distance when the transfer efficiency is 50% and it can be calculated from the following equation:
In Eq. 7, k 2 is the spatial orientation factor of the dipole, N is the refracted index of medium, and ĭ is the fluorescence quantum yield of the donor. J is the effect of the spectral overlap between the emission spectrum of the donor and the absorption spectrum of the acceptor (Fig.6) . Therefore, In the present experimental conditions, k=2/3, n=1.336, ĭ=0.15 [8] . According to the Eqs. (6)- (8) , R 0 = 2.00 nm, E = 0.301, and r = 2.30 nm. As the distance of donor to acceptor for NZ-105-BSA complex is in the 2-8 nm scale, non-radiative energy transfer occurs between NZ-105 and BSA with high probability.
F. Binding studies in the presence of ANS
When two different kinds of drugs are simultaneously administrated, it is possible that one drug competes with the other for the binding sites on albumin in blood plasma. The fluorescence studies were supplemented with the experiment of competitive binding of fluorescent probe 1-anilinonsphthalene-8-sulfonic acid (ANS), which is one of the most universally used model drug in protein research in the presence of NZ-05. The fluorescence spectra of BSA shown both NZ-105 and ANS quenched the fluorescence of BSA. The binding capacity of BSA to ANS/NZ-105 can be evaluated by the fraction of occupied sites (ș) described as follows:
where F 0 and F are fluorescence intensities measured at the maximum of the emission band, in the absence and presence of ANS/NZ-105, respectively. The value of ș for ANS-BSA system was 85%, whereas for NZ-105-BSA system, it was 53%, which suggested that the magnitude of decrease in fluorescence intensity was much larger for ANS as compared to that for NZ-105, This means that the interaction of ANS with BSA was stronger than that of NZ-105 with BSA, which may be explained as that the tryptophan residues are fully accessible to hydrophobic probe ANS but are only partially accessible to NZ-105.
Next, BSA-ANS interaction was studied upon gradually addition of NZ-105 by monitoring the changes of ANS fluorescence intensity upon excitation at 370 nm. It was observed that fluorescence intensity of ANS exhibited a slight decrease upon addition of NZ-105 (data not showed). This suggested that NZ-105 displaced ANS from its binding site.NZ-105 can compete with ANS for hydrophobic sites on the surface of BSA, which means ANS and NZ-105 do share common sites in BSA. 
G. Influences of common ions on binding constant
Common ions are widely distributed in human plasma, which has definite ability to bind the proteins, hence affect the binding of drugs to albumin. To investigate the effect of coexistent ions on drug-albumin binding, the binding constants were investigated in the present of various ions. The values of binding constant K A as acquired are listed in Table 4 .
As is shown in 
